

Patients enrolled in the PRINTO projects

Country	Pharmachild	EPOCA	Eurofever	MAS
Albania			1	
Algeria		140		
Argentina	124	473	37	39
Armenia			101	
Australia			10	1
Austria	25			
Belgium			13	15
Bosnia				2
Brazil	370	289	13	34
Bulgaria	56	300		
Canada		7	1	38
Chile		119	5	
China			25	20
Colombia		10		
Croatia	98	100	11	13
Czech R.	128	203	194	
Denmark	503	402	130	6
Finland		276		
France	148		284	29
Egypt		12		
Estonia		210		
Georgia		190	9	6
Germany		424	275	34
Greece	394	375	64	39
Hungary	124	297	24	
India	99	375	3	55
Iran		320		

Patients enrolled in the PRINTO projects

Country	Pharmachild	EPOCA	Eurofever	MAS
Israel	81	216	162	10
Italy	994	1245	713	338
Japan			6	7
Latvia	256	304	6	47
Lithuania	298	217	6	
Lybia		124		42
Mexico	12	199		1
Netherlands	366	317	97	9
Norway	206	375		5
Oman	16	143	6	
Paraguay		151		
Poland	30	248	5	
Portugal		82		
Romania	383	411	23	
Russia	452		43	15
Saudi Ar.	35	59	39	3
Serbia	272	349	4	6
Slovakia	123	208	1	
Slovenia	55	117	13	14
S.Africa		57		
Spain	661	483	133	39
Sweden		50	1	4
Switzerland	386	100	94	1
Turkey		454	165	131
UK		200	296	2
USA		413	6	98
Venezuela				8
Total	6695	11044	3019	1111

September 2014

Paediatric Rheumatology International Trials Organisation (PRINTO)



ADVISORY COUNCIL

Chairman

Alberto Martini, MD, Prof - Genova, Italy

Counsellors

Tadej Avcin, MD, MSc— Ljubljana, Slovenia

Michael Beresford, MD—Liverpool, UK

Susan Nielsen, MD—København, Denmark

Pierre Quartier, MD - Paris, France

Claudia Saad Magalhães, MD, PhD—Botucatu, Brazil

Nico Wulfraat, MD, PhD—Utrecht, The Netherlands

Senior Scientist

Nicola Ruperto, MD, MPH - Genova, Italy

IRCCS G. Gaslini

Pediatria II - PRINTO

Via Gaslini, 5

16147 Genova, ITALY

Tel: +39-010-38-28-54 or +39-010-39-34-25

Fax +39-010-39-33-24 or +39-010-39-36-19

E-mail: printo@ospedale-gaslini.ge.it

www.printo.it

www.pediatric-rheumatology.printo.it

21st NEWSLETTER

PRoS Congress 2014 Belgrade, Serbia
Saturday September 20th 2014
at 12.30-13.30, Main Hall

Agenda of the annual PRINTO General meeting

- Introduction (A. Martini)
- Update on PRINTO Projects (N. Ruperto)
- Pharmachild (N. Wulffraat, J. Swart, N. Ruperto)
- SHARE (P. Dolezalova, N. Wulffraat)
- MYPAN (P. Brogan)
- The PRES EuroFever project (M. Gattorno, S. Federici)
- EPOCA/MAS studies (A. Ravelli, A. Consolaro, F. Minoia)

The PharmaChild Project

This project is a retrospective and prospective registry with the aim to collect moderate-severe serious adverse events and related efficacy in JIA patients treated with biologics and/or MTX on a long-term period.

The project and related web database is now up and running (see attached table). The web data base has been created with the aim to be an international electronic resource for all PRINTO centres in order to collect safety and efficacy information on JIA patients. It will allow the immediate **graphic quantification** of the disease activity (JADAS, ACR, flare, inactive disease etc) status as well as the possibility to autonomously **download electronic data** for local research or other related purposes. The web system has been designed to be friendly enough to be used in **daily clinical practice**.

As of September 2014, 87 PRINTO centres have been activated. 10250 patients have been entered into the census, 6695 in the retrospective and 1259 in the prospective. The European Union grant (PI Dr N. Wulffraat 2011-2014) will be over in September 2014 **but it is likely that other funding will become available (see abatacept registry)**.

A dedicated Pharmachild meeting will be held during the PRES meeting on Thursday 18th September from 17.00h-18.00h in the Aegean Room.

The Abatacept JIA Registry

This project is an observational registry financed by Bristol-Myers Squibb (Prot. IM101240) that aims to describe the long-term safety of the abatacept treatment for JIA in routine clinical practice. The registry is a **sub-study of the PharmaChild project (scientific data property of PRINTO)** meaning that the registry will use exactly the same prospective case report forms and web resources with a complete freedom to publish the related results. The study is conducted by PRINTO in collaboration with PRCSG (for North American sites). Administrative aspects (ethics committees, contracts and local monitoring) will be handled by the CRO inVentiv Health. As of September 2014, 47 PRINTO centres from 19 countries have agreed to participate in this study.

The EPOCA study (EPidemiology, treatment and Outcome of Childhood Arthritis)

The study is aimed at photographing the current status of children with

JIA across continents and countries. PRINTO national coordinators (NCC list at www.printo.it) were asked firstly to translate and cross-culturally validate the parent and child versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) and secondly to assess 100 consecutive JIA patients and 100 healthy children. Additional centres are participating by collecting each 100 consecutive JIA patients. The national language translations of the JAMAR will be published in a dedicated supplement on a rheumatologic journal. The aim of this study is therefore twofold:

- 1) to foster regular use of parent/patient-reported outcomes in paediatric rheumatology practice;
- 2) to obtain information about the frequency of ILAR categories, treatment modalities, and current outcome of JIA around the world.

As of today 50 translations have been completed and other 4 are in progress (see www.printo.it/jamar.asp). The data collection phase started in 2011 through a dedicated web database on the PRINTO member area and as of today more than 7500 JIA patients and 3500 healthy controls have been collected.

The PRES Eurofever project.

The PRES Eurofever project. The Eurofever Registry (PI Dr M. Gattorno) aims to increase the knowledge on the clinical presentation, response to treatment and complication of Autoinflammatory Diseases. A new longitudinal section is being implemented. The registry is fully enrolling; a total of 3019 patients have been enrolled so far: among them 283 with CAPS, 441 with CRMO, 856 with FMF, 184 with MKD, 594 with PFAPA and 266 with TRAPS. New papers have been recently published (see list on next page). Other publications are ongoing: first paper on MKD and PAPA, new evidence based PFAPA criteria, diagnostic/classification criteria for monogenic periodic fevers. Web database update to be put online soon: new diseases and a new longitudinal section dedicated to treatment efficacy, safety and quality of life

The SHARE project

The "Single Hub and Access point for paediatric Rheumatology in Europe" (SHARE) is a European project whose main objective is to provide the European countries with recommendations for the care of children with rheumatic disease, based on systematic literature reviews and on the online surveys sent by PRINTO to individual centres belonging to its network all over the world.

To identify the specific needs for the optimal care in PRD an online survey has been implemented (www.printo.it/SHARE) and already more than 250 PRINTO and PRES members have answered (150 national coordinators or centre directors).

Another important aim of the project is to update and enrich the PRINTO website for families. The site (<http://www.printo.it/pediatric-rheumatology>), visited by more than 11.000 per day, offers scientific information regarding the pediatric rheumatic diseases (PRD), the list of centres dealing with PRD, and the list of the family associations in more than 50 languages. We are now working

on the renewal of the website, and the diseases description texts have been updated in English; they are now ready for translation (PI Dr N. Wulffraat, EU project number 2011 1202).

The MAS criteria study

The MAS Criteria Study is an international and multinational project, aimed to develop a new set of classification criteria for sJIA-associated MAS. The data collection is over with 1111 patients collected: 362 patients with sJIA-associated MAS, 404 with acute flare of sJIA, 345 with febrile systemic infection. First results of the statistical evaluations on this large sample database have been recently published. In March 2014 the third phase of the project has been completed with the International Consensus Conference on MAS Classification Criteria, held in Genoa (Italy), and a consensus on a new set of classification for sJIA-associated MAS was reached (to be presented during PRES). The next step of the project will be the validation of the new set of classification criteria on a new cohort of MAS patients.

The Abirisk project

This project (Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk, www.abirisk.eu, Innovative Medicines Initiative Grant Agreement nr. 115303) aims to provide an integrated approach to investigate anti-drug antibody formation in JIA treated with biopharmaceuticals. The Abirisk project is conducted by PRINTO as a Pharmachild registry substudy (same case report forms) and the goal is to collect, besides clinical information, biosamples (Serum and RNA) of 200 children with JIA, newly treated with adalimumab, etanercept or tocilizumab at start and follow-up (total 6 study visits).

New onset JDM trial

The enrollment of the trial is now closed with 139 patients randomized from 55 centres in 23 countries. No major safety concern identified since last year. The analysis of the data has been completed. The first paper has been submitted.

The MYPAN trial in Childhood Polyarteritis Nodosa (PAN)

An Open Label Randomised Controlled Trial of Mycophenolate Mofetil (MMF) Versus Cyclophosphamide (CYC) for the Induction of Remission of childhood PAN Sponsored by University College London and coordinated by the Children Hospital in Liverpool and PRINTO is underway. MYPAN will investigate the comparative efficacy and safety of MMF (experimental treatment) vs CYC (standard treatment) for induction of remission of childhood PAN. This will be the first ever randomized trial for childhood PAN. As of today 36 centres have shown interest in participating in MYPAN and we are currently working to start the submission procedures to the regulatory authorities and ethics committees in these centres (PI Dr P. Brogan).

Membership

In 2014, PRINTO has reached 1189 effective members in 490 centres from 78 countries (with an increase in members of 21%).

WELCOME ABOARD!

If you wish to become a PRINTO member and receive regular updates about our research activity and invitations to our projects please go to:

<https://www.printo.it/membership.asp>

Your cooperation will be more than welcome and your effort will be essential for the research in the field of paediatric rheumatic diseases

For more info: printo@ospedale-gaslini.ge.it

Recent PRINTO publications

For reprints go to www.printo.it and click on "papers".

- Ruperto N, Vesely R, Saint-Raymond A, Martini A for the Paediatric Rheumatology International Trials Organisation (PRINTO). The impact of the European paediatric legislation in pediatric rheumatology: past present and future. *Ann Rheum Dis* 2013; 72:1893–189.
- Ozen S, Demirkaya E, Amaryan G, Koné-Paut I, Polat A, Woo P, Uziel Y, Modesto C, Finetti M, Quartier P, Papadopoulou-Alataki E, Al-Mayouf SM, Fabio G, Gallizzi R, Cantarini L, Frenkel J, Nielsen S, Hofer M, Insalaco A, Acikel C, Ozdogan H, Martini A, Ruperto N, Gattorno M; for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever Project. Results from a multi-centre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. *Ann Rheum Dis* 2014;73:662–667.
- Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, Kobusinska K, Zuber Z, Mouy R, Rumba-Rozenfelde I, Breda L, Dolezalova D, Job-Deslandre C, Wulffraat N, Alvarez D, Zang C, Wajdula J, Woodworth D,

Vlahos B, Martini A, Ruperto N, for the Paediatric Rheumatology International Trials Organisation (PRINTO). Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. *Ann Rheum Dis* 2014;73:1114–1122.

- Bohm M, Gonzalez Fernandez MI, Ozen S, Pistorio A, Dolezalova P, Brogan P, Barbano G, Sengler C, Kleingitman M, Quartier P, Fasth A, Herlin T, Terreri MT, Nielsen S, van Rossum MA, Avcin T, Castell ER, Foeldvari I, Foell D, Kondi A, Koné-Paut I, Kuester RM, Michels H, Wulffraat N, Amer HB, Malattia C, Martini A, Ruperto N for the Paediatric Rheumatology International Trials Organisation (PRINTO), Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis), *Pediatr Rheumatol Online J.* 2014 May 26;12:18.
- Consolaro A, Ruperto N, Bracciolini G, Frisina A, Gallo MC, Pistorio A, Verazza S, Negro G, Gerloni V, Goldenstein-Schainberg C, Sztajn bok F, Wulffraat NM, Martini A, Ravelli A, for the Paediatric Rheumatology International Trials Organization (PRINTO). Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. *Ann Rheum Dis* 2014 Jul;73(7):1380-3
- Rothmund F, Gerss J, Ruperto N, Däbritz J, Wittkowski H, Frosch M, Wulffraat NM, Wedderburn LR, Holzinger D, Gohar F, Vastert SJ, Brik R, Job Deslandre C, Melo-Gomes JA, Saad Magalhães C, Barcellona R, Russo R, Gattorno M, Martini A, Roth J, Foell D for the Paediatric Rheumatology International Trials Organization (PRINTO). Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. *Arthritis Care Res* 2014 Jun;66(6):949-55.
- Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E,

Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gámir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F; for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG), Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial, *Ann Rheum Dis* 2014; [Epub ahead of print]

- Lachmann HJ, Papa R, Minden K, Obici L, Touitou I, Cantarini L, Frenkel J, Anton J, Kone-Paut I, Cattalini M, Bader-Meunier B, Insalaco A, Hentgen V, Merino R, Modesto C, Toplak N, Berendes R, Ozen S, Cimaz R, Jansson A, Brogan P, Hawkins PN, Ruperto N, Martini A, Woo P, Gattorno M for the Paediatric Rheumatology International Trials Organisation (PRINTO), the Eurotraps and the Eurofever Project. The phenotype of TNF-receptor associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the EUROFEVER/EUROTRAPS international registry. *Ann Rheum Dis* 2013; [Epub ahead of print]
- Piram M, Koné-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, Stojanov S, Simon A, Finetti M, Sormani MP, Martini A, Gattorno M, Ruperto N, on the behalf of EUROFEVER, EUROTRAPS and PRINTO. Validation of the auto-inflammatory disease activity index (AIDAI) for hereditary recurrent fever syndromes. *Ann Rheum Dis* 2013; [Epub ahead of print]
- R. Levy, L. Gérard, J. Kuemmerle-Deschner, H. Lachmann, I. Koné-Paut, L. Cantarini, P. Woo, A. Naselli, B. Bader-Meunier, A. Insalaco, S. M. Al-Mayouf, S. Ozen, M. Hofer, J. Frenkel, C. Modesto, I. Nikishina, T. Schwarz, S. Martino, A. Meini, P. Quartier, A. Martini, N. Ruperto, B. Neven, and M. Gattorno for PRINTO and Eurofever A phenotype and genotype of cryopyrine associated periodic syndrome (CAPS) : a series of 136 patients from the Eurofever international registry. *Ann Rheum Dis* 2014; [Epub ahead of print]